Spero Therapeutics Inc (SPRO)
Spero Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing treatments involving bacterial infections. Co.'s product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial pulmonary disease. Co.'s partnership-directed programs consist of tebipenem pivoxil hydrobromide, which is designed to be oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections; and SPR206, which is an IV-administered antibiotic being developed as an option to treat multi-drug resistant Gram-negative bacterial infections in the hospital setting.
Company Name: |
Spero Therapeutics Inc |
Website: |
www.sperotherapeutics.com |
Sector: |
Biotechnology |
Number of ETFs Holding SPRO: |
3 |
Total Market Value Held by ETFs: |
$2.43M |
Total Market Capitalization: |
$76.00M |
% of Market Cap. Held by ETFs: |
3.19% |
|
|
April 28, 2024 5:42 PM Eastern
Buy (3.33 out of 4)
46th percentile
|
|